CPA
SGMT icon

Capital Performance Advisors’s Sagimet Biosciences SGMT Stock Holding History

Capital Performance Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500
Closed -$1.39K – 2245
2024
Q3 		$1.39K Buy
+500
New +$1.54K ﹤0.01% 1746

Other funds holding SGMT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Capital Performance Advisors's SGMT Position: Q4 2024 in Review

Capital Performance Advisors sold out of Sagimet Biosciences (SGMT) in Q4 2024, closing a stake of 500 shares — an estimated $1.39K sold.

Capital Performance Advisors first reported a position in SGMT in Q3 2024 and held it in 1 quarter. The position peaked at $1.39K in Q3 2024. 66 funds tracked by Wall St. Rank hold SGMT as of Q4 2024.

  • Capital Performance Advisors reported no remaining Sagimet Biosciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 500 Sagimet Biosciences shares in Q4 2024, an estimated $1.39K.
  • Capital Performance Advisors first reported a position in Sagimet Biosciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Sagimet Biosciences position peaked at $1.39K in Q3 2024.
  • 66 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.